How Candida albicans responds to stress in the body
Regulation of Candida albicans gene expression in response to host environmental stresses
This study looks at how the Candida albicans fungus changes its behavior when it faces challenges in the body, especially in people with weakened immune systems like organ transplant recipients and cancer patients, to find new ways to treat infections caused by this fungus.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-10867738 on NIH RePORTER |
What this research studies
This research investigates how the fungus Candida albicans adapts its gene expression when faced with various environmental stresses in the human body. It focuses on understanding the mechanisms that allow this pathogen to survive in immunocompromised individuals, such as organ transplant recipients and cancer patients. By exploring the role of specific proteins involved in the translation process, the research aims to uncover new targets for antifungal treatments. The approach includes studying the effects of different stressors on the fungus and how these influence its ability to cause infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are immunocompromised individuals, including those undergoing chemotherapy, organ transplant recipients, and patients with AIDS.
Not a fit: Patients with healthy immune systems or those not infected with Candida albicans may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antifungal therapies that are more effective against Candida infections.
How similar studies have performed: Other research has shown promise in targeting translation mechanisms in fungi, suggesting that this approach could yield significant advancements in antifungal treatments.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Kadosh, David — University of Texas Hlth Science Center
- Study coordinator: Kadosh, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.